Etzer Darout
Stock Analyst at BMO Capital
(1.64)
# 1622
Out of 5,218 analysts
117
Total ratings
41.56%
Success rate
18.87%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Q32 Bio | Maintains: Outperform | 64 22 | 3.69 | 496.21% | 2 | Dec 12, 2024 | |
Tourmaline Bio | Initiates Coverage On: Outperform | 50 | 21.89 | 128.41% | 1 | Dec 6, 2024 | |
Protagonist Therapeu... | Initiates Coverage On: Outperform | 62 | 41.15 | 50.67% | 1 | Dec 6, 2024 | |
Nurix Therapeutics | Initiates Coverage On: Outperform | 35 | 20.21 | 73.18% | 1 | Dec 6, 2024 | |
Kymera Therapeutics | Initiates Coverage On: Market Perform | 55 | 41.98 | 31.01% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 21 | 7.52 | 179.26% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 63 | 20.51 | 207.17% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 90 88 | 19.42 | 353.14% | 2 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 28 27 | 7.08 | 281.36% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 132 134 | 86.68 | 54.59% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 32 34 | 24.05 | 41.37% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 46 48 | 20.16 | 138.1% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 118 120 | 98.34 | 22.03% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 29 36 | 35.01 | 2.83% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 34 38 | 42.06 | -9.65% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 19 26 | 6.71 | 287.48% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 26 25 | 9.37 | 166.81% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 8 5 | 3.2 | 56.25% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 20 20 | 4.38 | 356.62% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 84 91 | 42.8 | 112.62% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 7 6 | 1.82 | 229.67% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 4 4 | 1.08 | 232.41% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 123 122 | 120.2 | 1.5% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 80 82 | 66.58 | 23.16% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 31 | n/a | n/a | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 2.42 | 395.87% | 2 | Sep 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 20 19 | 5.32 | 257.14% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 179 229 | n/a | n/a | 4 | Mar 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 170 | 245.25 | -30.68% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 84 | 5.72 | 1368.53% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 60 | n/a | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 38 | n/a | n/a | 5 | Mar 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 54 | 28.86 | 87.11% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 27 38 | 42.34 | -10.25% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 54 52 | 3.23 | 1509.91% | 1 | Mar 28, 2018 |